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known as the ‘‘ryanodine receptor’’ [RYR1]) as a pointThe further nosology is pursued, the more clearly does it
of entry into the syndrome’s pathophysiological cascade.emerge that in every case of every malady there are two
sets of factors at work in the formation of the morbid The mutation, an adenine-for-guanine substitution at
picture, namely the internal or constitutional factors, in- nucleotide 3333, confers an arginine-to-histidine transi-
herent in the sufferer, and usually inherited from his for- tion at amino acid 1086. Three previously identiﬁed
bears, and external ones which ﬁre the train. (Garrod
substitutions for arginine residues elsewhere in CAC-1931, pp. 146–147)
NL1A3 cause the neuromuscular disease hypokalemic
This year marks the 150th anniversary of the ﬁrst public periodic paralysis (HOKPP1) (Jurkat-Rott et al. 1994;
demonstration of the use of anesthesia in surgery. The Ptacek et al. 1994), which itself may predispose to malig-
event was so startling in its lack of antecedents and nant hyperthermia (Lambert et al. 1994). Publication
profound in its applications that, despite the lack of of Monnier et al.’s contribution provides an opportune
technologies of mass communication, news of William landmark for taking stock of research aimed at elucidat-
Morton’s successful use of sulfuric ether reached the ing the genetic substrate of malignant hyperthermia thus
ends of the earth within weeks (Pernick 1985). More far and for surveying the distance ahead.
than 100 years were to elapse before malignant hyper-
thermia, a lethal consequence of the use of ether and The Malignant-Hyperthermia Phenotype: Clinical
its related compounds, was ﬁrst recognized by Michael Features and the In Vitro Contracture Test
Denborough, then a medical student in Australia. Den-
Shortly after Denborough’s account, the clinical syn-borough’s insight was twofold—ﬁrst, in identifying the
drome was ﬂeshed out in full. Fulminant muscle rigidity,disorder as a distinct entity and, second, in apprehending
rhabdomyolysis, hypercarbia, and acidosis following in-that susceptibility could be inherited (Denborough and
halation of volatile anesthetics and parenteral injectionLovell 1960). The curious failure on the part of preced-
of depolarizing muscle relaxants are the cardinal clinicaling generations of anesthesiologists to detect malignant
features. Elevated core temperature is common, but nor-hyperthermia arose less from its presumed rarity—or
mothermia does not rule out the diagnosis. Hyperther-from the intellectual handicap of those attracted to the
mia may be a late sign, as in the proband described byﬁeld—than from the time and collective experience re-
Monnier et al. (1997), and triggering agents must bequired to learn how to safely administer drugs capable
discontinued at the earliest suspicion. Hyperkalemia andof killing in so many different ways.
increased serum creatinine phosphokinase accompanyIn this issue of the Journal, Monnier et al. describe
the perioperative crisis but have not proved to be usefulthe ﬁrst mutant allele in the second gene to be associated
markers of malignant-hyperthermia susceptibility. Ven-with human malignant hyperthermia on the basis of
tricular dysrhythmia is the proximate cause of death inlinkage analysis (Monnier et al. 1997). The gene CAC-
the acute event, with renal failure and neurologic injuryNL1A3, which encodes the channel-forming a1s subunit the feared sequelae. The international incidence of ma-of the skeletal muscle L-type voltage-dependent calcium
lignant hyperthermia is estimated to be 1/50,000 anes-channel (VDCC) (also known as the ‘‘dihydropyridine
thetics. Children are at special risk, with Ç1/5,000–receptor’’), joins the calcium-release channel (also
10,000 pediatric anesthetics using trigger drugs compli-
cated by a malignant-hyperthermia crisis. A higher
incidence is encountered in geographically deﬁned popu-
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hyperthermia had become the preferred components of lignant-hyperthermia triggers. Clinicians are reluctant
to abandon their use, because of the precise and rapidmost general anesthetics. Particularly in emergencies, a
family history of anesthetic complications is often un- control, over depth of anesthesia, that anesthetic vapors
provide. As a class, the halogenated agents produce skel-available, and susceptible patients may exhibit no spe-
ciﬁc antecedent phenotype. To make matters worse, a etal, cardiac, and smooth-muscle relaxation in normal
patients, in stark contrast to the rigidity and contractureprior history of an uneventful anesthetic using triggering
drugs does not assure that a subsequent anesthetic will observed in those susceptible to malignant hyperther-
mia. None of the volatile agents depolarize normal mus-be safe (Halsall et al. 1979). These uncertainties were
resolved in part by introduction of the in vitro halothane cle, despite small elevations in myoplasmic calcium, and
the mechanism of relaxation is not known. Althoughcontracture test (IVCT) (Kalow et al. 1970; Ellis and
Harriman 1973), in which strips of biopsied muscle are their lipophilicity assures access to any tissue or subcel-
lular compartment, no protein targets expressed in skel-suspended in a bath and electrically stimulated. Abnor-
mally high levels of tension in the presence of caffeine etal muscle that are speciﬁc for the volatile anesthetics
have been found. The potent agents are metabolized toand halothane added to the bathing solution are gener-
ated in the muscle of individuals susceptible to malig- varying degrees in the liver, but none of the metabolites
are noteworthy myotoxins, nor are the responsible en-nant hyperthermia. The IVCT focused experimental ef-
forts on skeletal muscle as the primary site of the defect, zyme pathways aberrant in malignant hyperthermia. To
date, clues to the mechanisms of muscle destruction inaway from earlier theories of neural or endocrine patho-
genesis, but it was not until 1984 in Europe and 1989 in individuals predisposed to malignant hyperthermia have
not been forthcoming from knowledge either of theNorth America that test centers agreed on standardized
protocols and cutoff points for clinical purposes. Data pharmacokinetic proﬁles of volatile anesthetics or of
their effects on normal tissue.collected before these dates are contaminated to an inde-
terminate extent by subjective interpretation, which Succinylcholine, a depolarizing muscle relaxant, is the
other drug capable of triggering malignant hyperther-could underlie the limited genotype-phenotypetype con-
cordance reported for putative mutant alleles in some mia, either alone or, as in the present proband, in coad-
ministration with a volatile anesthetic. Quick in onsetfamilies (Serfas et al. 1996).
Use of the IVCT for the differential diagnosis of malig- and short in duration, succinylcholine frequently is used
in pediatric anesthesia, to facilitate tracheal intubationnant hyperthermia is now fairly uniform, but divergent
strategies adopted for ascertainment and genetic coun- after loss of consciousness by inhalation of a volatile
drug. It is at this point in the perioperative course thatseling are reﬂected in the subsequent acquisition of mo-
lecular genetic data. IVCT centers in the United States patients susceptible to malignant hyperthermia most of-
ten become rigid, with a clenched jaw and rigid chestoften halt testing within a pedigree after identiﬁcation of
the ﬁrst positive result in the generation of the proband’s impairing ventilation. Succinylcholine binds to the neu-
romuscular junction, initiating a wave of depolarizationparents, since malignant-hyperthermia susceptibility is
assumed to be rare. In European and Canadian labora- within the sarcolemmal t-tubule system, seen clinically
as muscle fasiculations followed by paralysis. Becausetories, efforts are made to perform an IVCT on all of a
proband’s relatives at risk, laying the groundwork for succinylcholine is a charged quaternary ammonium
compound that cannot enter the cell, depolarization isgenetic investigations such as that by Monnier et al.
(1997). The IVCT remains indispensible in malignant- thought to be directly responsible for triggering a malig-
nant-hyperthermia crisis. The neuromuscular junctionhyperthermia diagnosis, counseling, and research (Hop-
kins et al. 1997); however, it is invasive, costly (as much has been intensely investigated as a possible site of the
malignant-hyperthermia defect, but no abnormalititesas $3,000), ill suited for use in early childhood, and
not widely available. The dismal record of numerous of the nerve terminal or motor endplate are found in
tissue from malignant-hyperthermia survivors; patientsattempts to improve or replace the IVCT have contrib-
uted greatly to interest in the potential of DNA-based with disorders of the neuromuscular junction (e.g., my-
asthenia gravis) are not at risk for malignant hyperther-approaches. It initially was hoped that hints in the search
for the genetic foundations of malignant hyperthermia mia; and neuromuscular blockade with nondepolarizing
muscle relaxants (curare-like compounds) does not pre-would be revealed by closer scrutiny of the triggering
drugs themselves. vent or treat the acute event. Succinycholine is catabo-
lized in the plasma by the enzyme pseudocholinesterase.
No cases of pseudocholinesterase deﬁciency, an autoso-External Factors
mal recessive disorder with an incidence of 1/3,000, have
been reported concomitant with malignant hyper-All halogenated ethers in contemporary clinical prac-
tice (i.e., isoﬂurane, ethrane, sevoﬂurane, and desﬂur- thermia.
Early recognition of a malignant-hyperthermia epi-ane), as well as halothane (an alkane), are potential ma-
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sode, as well as prompt intervention with intravenous been established in which malignant hyperthermia is in-
herited as an autosomal dominant trait in correlationdantrolene, a hydantoin congener introduced in 1977,
is life saving in 90% of victims. Dantrolene is highly with abnormal IVCT results (Nelson 1991). The pig
RYR1 mutation has been ruled out (Hogan et al., inlipid soluble, inhibiting calcium release from the skeletal
muscle sarcoplasmic reticulum rather than acting di- press). Candidate gene searches and linkage analysis us-
ing markers characterized as part of the Dog Genomerectly at the neuromuscular junction or on the t-tubular
membrane. A distinct protein receptor for dantrolene Project are underway. Whether a mutation in canine
malignant hyperthermia or in any other species will cor-recently has been proposed as a possible constituent of
the skeletal muscle triad at the site of apposition between respond to human malignant hyperthermia is unknown.
Abnormal regulation of calcium in skeletal muscle isthe terminal cisternae of the sarcoplasmic reticulum and
sarcolemmal t-tubules (Parness and Palnitkar 1996). Iso- the sine qua non of malignant hyperthermia; hence, pro-
teins known to participate in myoplasmic calcium ho-lation of this protein, as well as cloning of its gene,
potentially will yield an additional candidate for analysis meostasis may denote candidate genes. To initiate con-
traction in skeletal muscle, calcium stored in thein malignant-hyperthermia pedigrees. If so, a deeper un-
derstanding of the mode of action of the speciﬁc therapy sarcoplasmic reticulum is liberated by conformational
changes in the RYR1 protein that are transduced byfor malignant hyperthermia may reveal mutant alleles
that have eluded inquiry based on investigation of trig- the VDCC in response to t-tubule depolarization. The
critical role of the VDCC in excitation-contraction cou-gering drugs.
pling motivated earlier investigators to map, clone, se-
quence, and identify polymorphisms in CACNL1A3 en-Internal Factors
coding the VDCC channel-forming a1s subnunit as a
candidate for malignant hyperthermia. Although theThus far, primary genetic approaches have been much
more fruitful than deliberation over drug triggers and HOKPP1 CACNL1A3 mutations appear in regions of
the molecule that have been demonstrated, by the con-their antagonists, in directing discovery of genetic alter-
ations associated with malignant hyperthermia. Soon struction of experimental chimeral channels, to be volt-
age sensors, the site of the malignant-hyperthermia mu-after Denborough’s description, meat spoilage in an ani-
mal model sharing many features of the human syn- tation that Monnier et al. have found in the
intracytoplasmic loop spanning transmembrane repeatsdrome was reported in strains of pigs bred to produce
lean bacon (Hall et al. 1966). Abundant genetic and III and IV has not previously been assigned a physiologi-
cal role. Distinct isoforms encode the a1 subunits ofbiochemical evidence pointing to a disorder of the skele-
tal muscle calcium-release channel kindled a search for heart, neuroendocrine, and brain VDCCs, which coop-
erate in the assembly of channels with tissue-speciﬁca causal mutation in the porcine RYR1 gene, resulting
in isolation of a cysteine-for-arginine substitution at po- functional properties. Defects in the a1A subunit of the
brain-speciﬁc P/Q-type calcium channel gene (CAC-sition 615 of the pig RYR1 amino acid sequence (Fujii
et al. 1991). This alteration, which is responsible for all NL1A4) cause familial hemiplegic migraine and type-2
episodic ataxia (Ophoff et al. 1996), intimating thatmalignant-hyperthermia susceptibility in pigs, is found
in only a small proportion (5%) of human malignant- only the surface has been scratched in the isolation of
disease-causing mutations in this gene family. Other in-hyperthermia pedigrees. Until the present, as many as
12 additional point mutations in RYR1 are known to viting malignant hyperthermia–candidate proteins ex-
pressed in skeletal muscle include calsequestrin, whichcosegregate with human malignant hyperthermia. Some
appear in a small subset (2%–10%) of pedigrees, de- acts as a calcium buffer in the luminal space of the
sarcoplasmic reticulum (Kawasaki and Kasai 1994); tri-pending on the origin of the screened database; others,
including the ﬁrst deﬁnitive report of RYR1 malignant- adin, which may physically couple CACNL1A3 to
RYR1 (Brandt et al. 1992); the FK506-binding proteinhyperthermia homozygotes (Lynch et al. 1997), are con-
ﬁned to a single family. Additional mutant RYR1 alleles (FKBP12), which stabilizes the closed conformation of
the RYR1 (Timerman et al. 1993); and aldolase, whichremain to be found, since not all of the original families
showing chromosome 19 linkage in the region of RYR1 copuriﬁes with the triad and causes rhabdomyolysis in
deﬁcient patients (Kreuder et al. 1996).(MacLennan et al. 1990) are accounted for by mutations
identiﬁed to date. Linkage analysis based on IVCT phenotyping indi-
cates that RYR1 mutations will not be found in as manyEvents during veterinary anesthesia that resemble
those in human malignant hyperthermia are reported in as 50% of families with malignant hyperthermia (Ball
and Johnson 1993). Evidence for a second malignant-a wide variety of other species, including horses, cats,
and dogs. In most instances, clinical episodes and IVCT hyperthermia locus atCACNL1A3 is now ﬁrm, but both
RYR1 and CACNL1A3 have been exluded in other kin-data within a pedigree are not available to conﬁrm a
genetic predisposition. One breeding colony of dogs has dreds (Sudbrak et al. 1993). Linkage to a locus on chro-
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mosome 3q, with a LOD score of 3, has been reported spect, after an anesthetic death. Although the clinical
spectrum of King-Denborough syndrome might suggestfor a single family (Sudbrak et al. 1995), but no candi-
date genes are known to reside in the 1 cM of highest a contiguous-gene defect, normal karyotypes in one
male and in one female have been reported (Hogan etprobability. As Monnier et al. (1997) point out, a fourth
locus on chromosome 7q, in proximity to the gene en- al. 1994). The RYR1 R614Cmutation was not observed
in either child. Events resembling malignant hyperther-coding the VDCC a2/d subunit, also has been linked to
malignant hyperthermia in a single family, but a causal mia also have been described in a small number of other
dysmorphic conditions (Schwartz-Jampel syndrome,mutation has yet to be disclosed (Iles et al. 1994). Se-
quencing efforts in the latter two regions not only have Noonan syndrome, and some forms of arthrogryposis),
but it is unclear whether these are pathologically relatedthe potential to identify new malignant-hyperthermia
loci but may bring to light hitherto unidentiﬁed molecu- or coincidental associations.
lar participants in excitation-contraction coupling.
Investigators are divided over how to best categorize Summing Up
malignant-hyperthermia events and positive IVCT re-
In the search for all genetic alterations taking part in
sults observed in patients with recognizable coexisting
the pathogenesis of human malignant hyperthermia, a
neuromuscular diseases (e.g., Duchenne muscular dys-
single CACNL1A3 mutation now can be added to a
trophy, carnitine parmitoyl transferase II deﬁciency, and
dozen or so RYR1 mutations already identiﬁed. It is
Brody myopathy [a deﬁciency of the Ca2/-ATPase
highly probable that additional RYR1 mutations will be
pump]). One opinion holds that, if a myopathy can be
characterized in the near future, and it is reasonable
diagnosed by signs, symptoms, and clinical tests without
to anticipate that new CACNL1A3 mutations will be
an IVCT, it is not ‘‘true’’ malignant hyperthermia and
detected as inventories are screened on the heels of the
that only otherwise normal individuals with a positive
present publication. If so, will the tight genotype-pheno-
IVCT ﬁt the nosology. Others argue that malignant hy-
type correlation described by Monnier et al. (1997) hold
perthermia is a clinical syndrome, not a single disease,
up, or will the story more nearly resemble that described
with many myopathic disease inlets to a shared patho-
for many of the RYR1 mutations, in which the extent
physiological pathway that is initated by elevated myo-
of concordance varies from family to family, for each
plasmic calcium. In providing the ﬁrst positive evidence
mutation? In all likelihood a third locus on chromosome
for locus heterogeneity in the absence of a concurrent
3q and a fourth on chromosome 7q (the VDCC a2/disease phenotype, the contribution of Monnier et al.
d gene) will yield malignant hyperthermia–associated
(1997) upholds the latter point of view. IVCT results
candidate mutations. Because human malignant hyper-
from this family with a CACNL1A3 mutation are indis-
thermia is a genetically diverse syndrome with clear-cut
tinguishable from IVCT abnormalities compiled from
evidence of both locus and allelic heterogeneity, genes
families with a disorder of the RYR1 gene; hence, the
responsible for otherwise recognizable neuromuscular
IVCT as presently conﬁgured fails to discriminate be-
diseases mediated by calcium-induced injury must be
tween diseases predisposing to the malignant-hyperther-
considered possible candidates for additional mutant al-
mia syndrome. The practical—and nontrivial—clinical
leles. Finally, it is too early to tell whether a second
consequence is that all myopathic conditions suspected
animal model will correspond to human malignant hy-
to be mediated by calcium injury must be considered
perthermia, or if a microdeletion will be associated with
susceptible to malignant hyperthermia, and selection of
malignant hyperthermia in patients with dysmorphic
the anesthetic technique and management of crises must
syndromes.
be handled accordingly. The telling research corollary
is that documentation of allelic heterogeneity in both
When Should Surgical Patients Be Genotyped?
RYR1 (with mutant alleles causing both central core
disease and malignant hyperthermia) and CACNLlA3 Informed use of the data in the present manuscript,
for anesthetic management and counseling of family(with mutant alleles causing both HOKPP1 and malig-
nant hyperthermia) compels a search of genes mutated members at risk, is constrained by the conﬁdence with
which the CACNL1A3 R1086H mutation can be pre-in well-recognized neuromuscular disorders, for alter-
ations that make their presence felt only in environments sumed to be causal. Arguments favoring causality for
this mutation are based strictly on statistical criteria inof triggering anesthetic drugs.
Malignant hyperthermia associated with short stat- the absence of biological evidence. The mutation is de-
scribed in only one moderate-sized family with a singleure, myopathy, micrognathia, low-set ears, and variable
additional features (e.g., cryptorchidism and pectus car- clinical episode of malignant hyperthermia; the proband
could not be analyzed for the mutation; IVCT resultsniatum) is recognized as King-Denborough syndrome
(McPherson and Taylor 1981). Tragically, the diagnosis are available from just two generations; three of the
IVCT results are equivocal; and the ‘‘normal’’ chromo-of this extremely rare disorder usually is made in retro-
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somes screened for the mutation were from IVCT-nega- coming to surgery? Clearly, a patient lacking known
mutations is at somewhat less risk than the unscreenedtive patients from other malignant-hyperthermia pedi-
grees. That the RYR1 R614C mutation is associated population—but also is at risk somewhat greater than
zero. Vigilance for early signs of a trigger and immediatewith a similar phenotype in two species argues in sup-
port of its causality, but, unless additional animal mod- access to dantrolene therefore will remain essentials of
anesthetic practice, for long into the future. But an indi-els of human malignant hyperthermia are discovered,
this criterion is too stringent to be met by subsequent vidual found to carry one (or more) causal malignant-
hyperthermia mutations could beneﬁt in the extreme bymutations. Construction of a transgenic animal for each
mutant allele is not feasible, but a comparison of the selection of an alternative risk-free anesthetic. Estimates
of the incidence of known malignant hyperthermia–as-functional properties of normal and mutant CAC-
NL1A3 cDNAs, particularly if they are expressed in the sociated alleles in the general population are crude at
present, but barriers to procuring this information arepresence and absence of triggering agents, will be key
to the validation, beyond all reasonable doubt, of the surmountable. The cost of a crisis, long-term care for
injured patients, and years of productive life lost to acausality of the mutations.
Would a prudent anesthesiologist, given foreknowl- syndrome that chieﬂy afﬂicts the young and ﬁt can be
estimated. If savings in morbidity and mortality out-edge of a causal malignant-hyperthermia mutation seg-
regating in a family, administer a trigger anesthetic to weigh the expense of genetic screening, perioperative
genotyping for malignant-hyperthermia mutant allelesmembers testing negative for that mutation? I believe
not. At present, not only are we ignorant of the total soon may guide anesthesiologists in judging when to
keep their hands off the throttle—and when to pour onnumber of predisposing mutations, but the population
frequency, new mutation rate, incidence of phenocopies, the coal.
and extent of penetrance and expressivity for any malig-
nant hyperthermia–associated mutation are unknown.
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